Treatment of metastatic melanoma: an overview.
暂无分享,去创建一个
[1] V. Sondak,et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Steinberg,et al. Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines , 2008, Clinical Cancer Research.
[4] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[5] M. Guida,et al. Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study , 2008 .
[6] A. Hauschild,et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma , 2008 .
[7] G. Linette,et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Lorigan,et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Steinberg,et al. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.
[10] I. Quirt,et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. , 2007, The oncologist.
[11] A. Hauschild,et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma , 2007 .
[12] R. Gonzalez,et al. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma , 2007 .
[13] M. Gore,et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Einarson,et al. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. , 2006, Cancer treatment reviews.
[15] H. Pehamberger,et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Dummer,et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Ingle,et al. Combination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanoma , 2006, Cancer.
[18] D. Schadendorf,et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Atkins,et al. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial , 2005 .
[20] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Queirolo,et al. 837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma , 2003 .
[22] Jeffrey W. Clark,et al. Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma , 2002, American journal of clinical oncology.
[23] J. Lee,et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] O. Nanni,et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Manola,et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Atkins,et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.
[28] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Steinberg,et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Dummer,et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Pommier,et al. Surgical treatment of metastatic melanoma. , 1998, American journal of surgery.
[34] Q. Dong,et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Buzaid,et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] M. Ernstoff,et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up , 1995, Melanoma research.
[37] P. Queirolo,et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Morton,et al. The role of surgery in the treatment of nonregionally recurrent melanoma. , 1993, Surgery.
[39] P. Hersey,et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. , 1993, Melanoma research.
[40] R. Benjamin,et al. A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma , 1989, Cancer.
[41] D. Guerry,et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Casper,et al. Phase II trial of carboplatin in advanced malignant melanoma. , 1987, Cancer treatment reports.
[43] D. Ahmann,et al. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. , 1986, Cancer treatment reports.
[44] S. Prete,et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. , 1984, Cancer treatment reports.
[45] L. Baker,et al. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] E. Krementz,et al. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A) , 1984, Cancer.
[47] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] Takami Sato,et al. Paclitaxel and tamoxifen , 2000, Cancer.
[49] D. Khayat,et al. Fotemustine in the treatment of brain primary tumors and metastases. , 1994, Cancer investigation.
[50] A. Einzig,et al. Taxol in malignant melanoma. , 1993, Journal of the National Cancer Institute. Monographs.